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Abstract
A pancreatic pseudocyst (PPC) is typically a compli-
cation of acute and chronic pancreatitis, trauma or 
pancreatic duct obstruction. The diagnosis of PPC 
can be made if an acute fluid collection persists 
for 4 to 6 wk and is enveloped by a distinct wall. 
Most PPCs regress spontaneously and require no 
treatment, whereas some may persist and progress 
until complications occur. The decision whether to treat 
a patient who has a PPC, as well as when and with 
what treatment modalities, is a difficult one. PPCs can 
be treated with a variety of methods: percutaneous 
catheter drainage (PCD), endoscopic transpapillary or 
transmural drainage, laparoscopic surgery, or open 
pseudocystoenterostomy. The recent trend in the 
management of symptomatic PPC has moved toward 
less invasive approaches such as endoscopic- and 
image-guided PCD. The endoscopic approach is suitable 
because most PPCs lie adjacent to the stomach. The 
major advantage of the endoscopic approach is that 
it creates a permanent pseudocysto-gastric track with 
no spillage of pancreatic enzymes. However, given 
the drainage problems, the monitoring, catheter 
manipulation and the analysis of cystic content are very 
difficult or impossible to perform endoscopically, unlike 
in the PCD approach. Several conditions must be met 
to achieve the complete obliteration of the cyst cavity. 
Pancreatic duct anatomy is an important factor in the 
prognosis of the treatment outcome, and the recovery 
of disrupted pancreatic ducts is the main prognostic 
factor for successful treatment of PPC, regardless of 
the treatment method used. In this article, we review 
and evaluate the minimally invasive approaches in the 
management of PPCs. 
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review article presents and critically evaluates the 
minimally invasive approaches for the treatment of 
PPCs.
DIAGNOSIS OF PPCS
The distinction between PPC and other similar entities, 
such as benign and malignant cystic lesions, vascular 
pathology such as pseudoaneurysms and hematomas, 
seromas, abscesses, and bilomas, is crucial in the 
decision to treat a patient who has a PPC, as well 
as when and by which method. This requires the 
correlation of often complex and overlapping clinical 
presentations and laboratory findings with those of 
imaging studies, such as ultrasound (US), computed 
tomography (CT), and magnetic resonance imaging 
(MRI)[15,16].
Clinical presentation and laboratory findings
PPC is typically asymptomatic, and its clinical 
presentation tends to occur in cases with complications 
throughout their clinical course. During physical 
examination, the most common presenting symptoms 
that might be attributed to the development of 
symptomatic PPC are persistent abdominal pain 
and/or an epigastric mass with a persistently raised 
serum amylase level[17]. Clinical presentations 
of PPC complications are infection, rupture and 
haemorrhage[7,17]. Infection occurs in approximately 
10% of cases and is characterized by fever and 
abdominal pain. The leakage of the content from the 
PPC into the peritoneum can cause the appearance of 
pancreatic ascites. However, sudden rupture of the PPC 
into the peritoneum produces severe peritonitis that 
is often fatal. Haemorrhage is caused by the erosion 
of the small vessels that line the cyst wall or the 
erosion of surrounding major blood vessels. Intracystic 
bleeding leads to a rapid enlargement of the PPC, 
which produces pain and shock. Spontaneous rupture 
of the PPC into the gastrointestinal tract can result in 
the drainage of its contents into the gastrointestinal 
tract and the amelioration of symptoms. However, this 
is often associated with vomiting, hematemesis and 
melena[17]. 
Laboratory findings have a limited value in the 
diagnosis of PPC. Serum amylase and lipase levels are 
persistently elevated in up to 76% of patients with 
PPC. When PPC produces a biliary obstruction, the 
serum bilirubin level is increased[17]. 
Imaging evaluation
The diagnosis of a PPC is usually established by 
imaging studies, whereby a rapid progress in the 
improvement of diagnostic modalities enables 
detection with high sensitivity and specificity. 
Because transabdominal ultrasonography is a very 
inexpensive and noninvasive technique, it should be 
performed as a first step in the diagnosis of PPCs. 
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Core tip: Pancreatic pseudocysts (PPCs) are common 
complications of acute and chronic pancreatitis, 
pancreatic trauma, and pancreatic duct obstruction. 
They can be treated with a variety of methods: percu-
taneous catheter drainage, endoscopic transpapillary 
or transmural drainage, laparoscopic surgery, or open 
pseudocystoenterostomy. It is a difficult decision 
whether to treat a patient with a PPC and if so, with 
what treatment modalities and when. This article 
presents and critically evaluates the minimally invasive 
approaches for the treatment of PPCs.
Zerem E, Hauser G, Loga-Zec S, Kunosić S, Jovanović P, Crnkić 
D. Minimally invasive treatment of pancreatic pseudocysts. 
World J Gastroenterol 2015; 21(22): 6850-6860  Available from: 
URL: http://www.wjgnet.com/1007-9327/full/v21/i22/6850.htm 
DOI: http://dx.doi.org/10.3748/wjg.v21.i22.6850
INTRODUCTION
A pancreatic pseudocyst (PPC) is defined as a collec­
tion of fluid in the peripancreatic or intra­pancreatic 
tissues, is surrounded by a well­defined wall and 
contains essentially no solid material[1]. PPCs are 
usually complications of both acute and chronic pancrea­
titis, pancreatic trauma, and pancreatic duct (PD) 
obstruction[2­6]. 
It is a difficult decision whether to treat a patient 
who has a PPC, and if so, when and with what 
treatment modalities. PPCs should initially be managed 
conservatively because many resolve spontaneously 
within 4 to 6 wk. Although most PPCs regress spon­
taneously and require no treatment, some (especially 
those larger than 6 cm) require treatment to prevent 
cystic infection, rupture, haemorrhage, and the 
resultant obstruction of the stomach, small bowel, 
colon or bile ducts[7,8]. 
Traditionally, surgical approach was the treatment 
of choice for symptomatic PPCs. Although surgery 
is effective, complications can occur in up to 35% 
of patients, and death from surgery has also been 
noted[9]. The recent trend in the management of 
symptomatic PPC has been toward less invasive 
approaches such as endoscopic and image­guided 
percutaneous catheter drainage (PCD)[2­13]. 
Several conditions must be met to achieve the 
complete obliteration of the cyst cavity. PD anatomy 
is an important factor for the prognosis and the 
treatment outcomes. When PPC­PD communication 
is identified, the mean duration of drainage increases 
to weeks or months, depending on the condition of 
the PD. The recovery of a disrupted PD is the main 
prognostic factor for successful treatment of PPC 
regardless of the treatment method[2,11,12,14]. This 
US has a diagnostic sensitivity of 75% to 90% in 
detecting PPCs and the technique is highly dependent 
on the experience of the examiner. It has a limited 
role in the assessment of small PPCs (smaller than 
10 mm). However, small PPCs are asymptomatic and 
without clinical significance, usually not requiring any 
treatment[2,17]. 
Endoscopic ultrasound (EUS) may typically display 
a small PPC, being the best method in distinguishing 
acute fluid collections from pancreatic abscesses 
and PPCs, with high sensitivity (93% to 100%) and 
specificity (92% to 98%)[18,19]. Besides, EUS can 
accurately define the proximity of the PPC to the gut 
lumen and surrounding large blood vessels. Limitations 
of EUS are its inability to demonstrate large PPCs 
which extend into peripancreatic areas in their entirety, 
and display PPCs which are more than 1 cm distant 
away from the gastric or duodenal wall[20,21]. 
CT scanning is a standard and precise imaging 
modality in the setting of PPCs, with 82% to 
100% sensitivity and 98% specificity. CT scan is 
more effective than US in detecting the secondary 
complications of a PPC, such as infection; hemorrhage, 
and involvement of adjacent structures[18,22]. 
Endoscopic retrograde cholangiopancreatography 
(ERCP) may be useful in patients who require 
delineation of PD anatomy, helping to devise optimal 
therapy. Although ERCP provides less information 
regarding the pancreatic size and surrounding visceral 
structures than CT and ultrasound, it renders important 
information on the anatomy of the pancreatic and 
biliary ductal system[14].
Magnetic resonance imaging (MRI) is a good 
alternative to CT for detection of PPCs due to its ability 
to characterize pancreatic and peripancreatic collections 
as partially or fully fluid in consistency. Magnetic 
resonance cholangiopancreatography (MRCP) may 
replace ERCP in the diagnostic evaluation of pancreatic 
duct. However, the diagnosis of PPC­PD communication 
is rather difficult because a communication can only be 
identified by MRCP if a high-intensity fluid tract can be 
detected between the pseudocyst and the duct[2,21,23­26]. 
A plain radiograph of the abdomen is rarely helpful 
in diagnosing PPC. Occasionally, it may demonstrate 
displacement of the gastric bubble or calcification in 
the cyst wall. A chest radiograph may show elevations 
of the diaphragm, pleural effusion, or a mediastinal 
mass.
Differential diagnosis between pseudocysts and cystic 
neoplasms
The differential diagnosis between PPCs and cystic 
neoplasms may be difficult in patients with a 
pancreatic fluid collection. Clinical criteria such as prior 
episodes of acute pancreatitis, and data regarding 
chronic pancreatitis or a calcified cystic wall less than 
1 cm thick, make the diagnosis of PPC more likely. 
On the contrary, weight loss, a palpable abdominal 
mass, the lack of pre­existing pancreatic disease, and 
multilocular cysts with non-calcified walls thicker than 
1 cm, all indicate the likelihood of a cystic malignant 
tumour. EUS or US­guided diagnostic puncture and 
sampling of the fluid content and of the PPC wall helps 
to distinguish cystic malignancies from PPCs[27­29]. 
Research has recently focused on the identification of 
new biomarkers for the diagnosis of malignant lesions. 
Important criteria for malignancy are a markedly 
elevated carcinoembryonic antigen (CEA) value in the 
cyst fluid (over 192 ng/mL) and increasing viscosity of 
the cyst content[18,30].
INDICATIONS FOR TREATMENT OF PPCS
The most important question in clinical practice 
related to acute or chronic PPCs is whether and when 
they should be treated. A careful preliminary clinical 
and imaging evaluation of benign pancreatic fluid 
collections can avoid unnecessary interventions. The 
majority of the simple PPCs are asymptomatic and 
do not require interventional treatment. Treatment is 
indicated if the complications are present or whether 
intervention is necessary to prevent complications. 
The indications for interventional procedures in the 
treatment of PPCs are summarized in Table 1.
Symptoms result from biliary obstruction, the 
effects of painful or obstructive masses, infection or 
haemorrhage into the cyst, pancreaticopleural fistula 
or compression of the surrounding major vessels, and 
in such cases, interventional treatment is typically 
indicated. Treatment is also indicated for symptomatic 
PPCs that cause abdominal distension, nausea and 
vomiting, pain, or gastrointestinal bleeding (Table 1). 
PPCs larger than 4 cm that develop outside the 
pancreas can be considered independent predictive 
factors of persistent symptoms because they rarely 
regress spontaneously and can cause complications[31]. 
Therefore, if they demonstrate either unchanged size 
and morphology or progression over a period of more 
than 6 wk of observation, these are relative indications 
for treatment[15,31]. A relative indication for treatment 
includes PPCs whose wall thickness is between 5 and 
10 mm and PPCs caused by the presence of chronic 
pancreatitis with duct abnormalities or stones in the 
PD. In these patients, constant irritation promotes 
inflammation and reduces the rate of spontaneous 
regression[18,31,32]. Whenever a malignant tumour is 
suspected, surgical treatment is urgently indicated 
(Table 1)[33,34]. When an intervention is required, the 
best option should be the application of a multidis­
ciplinary approach based on the initial imaging and 
clinical findings.
MINIMALLY INVASIVE APPROACHES TO 
THE MANAGEMENT OF PPCS
PPCs as benign fluid collections in the pancreas can 
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spontaneous resolution. The majority of pseudocysts 
that are over 6 cm in size that persist for over 
6 wk have been regarded as unlikely to resolve 
spontaneously[17,18,31,36]. However, some large PPCs (> 
6 cm) may undergo spontaneous resolution, which 
suggests that the size of the PPC alone is not an 
indication for drainage[36,37]. 
Chronicity adversely affects the healing of PPCs 
whereby PPCs that persist for 8 to 10 wk are unlikely 
to resolve spontaneously. Most PPCs that are likely to 
heal do so within 6 wk, but the resolution may occur 
after 24 wk or even 28 mo[17]. Chronic pancreatitis 
and pancreatic calcifications are also poor prognostic 
indicators[18,38].
Other factors that indicate that spontaneous 
regression is less likely include the presence of multiple 
cysts[18,39], location in the tail of the pancreas[37], and 
a wall thickness greater than 1 cm[40]. The aetiology 
may also have some bearing on the outcome. PPCs 
related to alcohol abuse have a more favourable 
outcome compared with those of biliary aetiology. 
However, traumatic PPCs may have a high percentage 
of spontaneous resolution[39].
The setting of non­interventional conservative 
management of PPCs is still poorly evaluated. Earlier 
studies showed that conservative treatment in the 
hope of spontaneous resolution was not without risks. 
Several studies have warned against serious, life­
threatening complications related to the conservative 
treatment of PPCs[41­44]. However, with improved 
medical care, the incidence of complications as well as 
the mortality rate has decreased considerably. Several 
studies[36,41,45,46] have reported that some patients with 
PPCs can be managed conservatively if the presenting 
symptoms can be controlled. According to their results, 
the complication rates with conservative management 
are low (< 1%). 
These results suggest that some patients with 
PPCs can be managed conservatively and that some 
pseudocysts can resolve with supportive medical care. 
Medical care includes the use of intravenous fluids, 
analgesics and antiemetics to control the presenting 
symptoms caused by PPC. For patients who can 
tolerate oral intake, a low fat diet is recommended, 
whereas for those who cannot tolerate oral nutrition, 
support can be provided via nasoenteral feeding or 
total parenteral nutrition[47].
Somatostatin (octreotide) has an inhibitory effect 
on pancreatic exocrine secretion, and it can be used 
to decrease the pancreatic secretion, which leads to 
the resolution of PPC. Octreotide has also been used 
in conjunction with PCD of PPCs, which results in a 
shorter drainage time. The role of somatostatin in 
the management of PPCs is not clear because this 
treatment has not been adequately tested and only 
a handful of case series have been published[47­49]. 
Prospective controlled trails are necessary to 
demonstrate its efficacy.
mimic cystic neoplasms. Therefore, pretreatment 
evaluations of pancreatic fluid collections for 
appropriate therapeutic intervention should be focused 
on the exclusion of cystic neoplasms that masquerade 
as pseudocysts[35]. The topic of cystic neoplasms of 
the pancreas is broad, and thus this article focuses 
primarily on the minimally invasive treatments of 
benign PPCs. Once a PPC has been diagnosed, it must 
be determined whether it can be treated conservatively 
in hopes of a spontaneous resolution, or whether an 
intervention is necessary to prevent complications. If 
an intervention is necessary, it must be determined 
whether surgical, PCD, or endoscopic drainage (ED) is 
the best approach. 
Conservative management
Based on earlier studies on the clinical course of PPCs, 
the rate of spontaneous resolution of PPCs has been 
reported to be from 8% to 70%[15,17,18]. This wide range 
can be attributed to many factors that influence PPCs, 
including size, chronicity, wall thickness, multiplicity, 
and aetiology. 
The size of the PPC is an important determinant of 
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Table 1  Indications for therapeutic intervention for pancreatic 
pseudocysts
Clinical presentations and complications
Local complications
   Infection of pancreatic pseudocyst
   Hemorrhage into pancreatic pseudocyst
   Rupture (can cause pancreatic ascites, shock and peritonitis)
Involving adjacent organs
   Gastrointestinal tract: 
      Esophagus (secondary achalasia, mechanical dysphagia)
      Stomach (clinically relevant gastric outlet stenosis, fistula, intramural 
      gastric mass)
      Duodenum (clinically relevant duodenal stenosis, fistula)
      Colon (clinically relevant colonic stenosis and/or rectal bleeding)
   Liver (stenosis of the common bile duct with jaundice due to 
   compression)
   Vascular:
      Arterial (erosion of gastroduodenal and/or splenic artery)
      Venous (thrombosis of portal and/or splenic vein)
   Spleen (splenic rupture)
   Genitourinary tract (stricture, fistula, ureter obstruction)
   Chest (pancreaticopleural fistula, pleural effusion, mediastinal 
   extension)
   Skin (subcutaneous fat necrosis)
Symptomatic pancreatic pseudocyst
   Abdominal distension
   Nausea and vomiting
   Pain
   Upper gastrointestinal bleeding 
Relative indications for intervention in asymptomatic pancreatic pseudocyst 
   Pseudocyst > 5 cm, unchanged in size and morphology for more than 
   6 wk[15]
   Pseudocyst > 4 cm and extrapancreatic complications in patients with 
   chronic alcoholic pancreatitis[31] 
   Cyst wall > 5 mm (mature cyst)[32]
   Chronic pancreatitis with advanced pancreatic duct changes[31]
   Suspected cystic pancreatic tumor (requiring surgery)[33,34]
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Image-guided percutaneous treatment of PPCs
Image­guided percutaneous drainage of PPCs is a well­
established and relatively inexpensive drainage method 
that involves either simple percutaneous aspiration or 
PCD. It is most commonly performed under ultrasound 
or CT control, and in some cases, under MRI or 
fluoroscopic guidance (Figure 1)[2,4,8,10,17,21,35,47,50­52]. 
Single­step needle aspiration of PPCs is associated 
with a high recurrence rate (70% or more) and 
cannot be considered the optimal treatment[4,8]. The 
continuous vacuum drainage system is more effective 
because it continuously evacuates the cyst content 
and thereby avoids the lytic action of pancreatic 
enzymes that may lead to obliteration of the cyst 
cavity. This approach has achieved high initial drainage 
success rates (70%­100%) and reduced recurrence 
rates[4,8,23,53].
Several conditions must be met to achieve the 
complete obliteration of the cyst cavity. PD disruption 
is the initial pathologic event that triggers PPC 
formation, and its anatomy is an important factor 
in the prognosis of the complete obliteration of the 
cyst cavity. Therefore, the complete removal of liquid 
and air, which is necessary to keep the cyst walls in 
close contact, constitutes the mechanical aspect of 
obliteration. The recovery of a disrupted PD has been 
recognized as the main prognostic factor for successful 
treatment of PPC regardless of the treatment method 
used[8,10,14]. Patients with PPC­PD communication 
require a longer duration of drainage, as short­
term drainage results in very high recurrence rates. 
However, some authors consider that the risk of septic 
complications is potentially increased with prolonged 
drainage periods[2,8,14,53­55]. 
Percutaneous techniques are usually performed 
under local anaesthesia and seem technically feasible in 
the vast majority of patients with PPCs. Transperitoneal, 
retroperitoneal, transhepatic, transgastric, and trans­
duodenal approaches are typically used. The access 
route for drainage depends on the size, location, and 
the disposition of the surrounding viscera and blood 
vessels[2,4,8,23,51]. Depending on the operator’s experience, 
the tandem trocar technique or the Seldinger technique 
may be used. If the Seldinger technique is used, the 
catheter tract should be sequentially dilated over a 
guidewire. The use of three­dimensional ultrasound 
and colour Doppler may help to guide the catheters 
into the cyst cavities and aid in the circumvention of 
major vascular structures, which increases the safety of 
the procedure[2,4,17,21,47,52]. 
After complete evacuation of the cystic content, the 
catheter should be secured to the skin and connected 
to a pressure bag for continuous external drainage. 
Catheter exchange may be performed as indicated. 
When the PPC has resolved and the drainage output 
becomes minimal (less than 10 mL/d), the catheter 
should be removed[8]. Percutaneous drainage is a 
safe and effective method for treatment of PPCs. 
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Figure 1  Appearance on ultrasound of a pancreatic pseudocyst before, during and after treatment. A: Appearance on ultrasound of a PPC in the tail of 
pancreas before treatment; B: Insertion of a catheter into the PPC; C: Residue of PPC with suspected PPC-PD communication (marked by arrows) immediately after 
the procedure; D: The appearance of the pancreas several months after the procedure. PPC: Pancreatic pseudocyst; PD: Pancreatic duct.
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Complications include catheter­related secondary 
infections (9%), bleeding (1%­2%), inadvertent 
traversing of the pleural space or other viscera 
(1%­2%), catheter occlusion, cellulitis at the site of 
entry, and sepsis[4,55]. Another limitation of PCD is 
the development of pancreaticocutaneous fistulae. 
However, the resulting pancreatic­cutaneous fistula 
spontaneously resolves with time in 60% to 70% 
of patients[4,56]. Moreover, in some cases, the fistula 
can be successfully treated by image­guided PCD[57]. 
In the case of superinfection or drainage problems, 
monitoring, catheter manipulation and analysis of the 
cystic content can be performed much more easily by 
PCD than by an endoscopic approach[8,21,58,59].
Endoscopic drainage of PPCs
ED provides minimally invasive access to the PPC, 
which may be performed by a trans­papillary or a 
trans­mural approach. Sometimes a combination of 
both methods may be necessary to drain a pseudocyst. 
ED is suitable because most PPCs lie adjacent to the 
stomach; however, both endoscopic and radiologic 
skills are required here. The aim of endoscopic 
treatment is to create a connection between the 
pseudocyst cavity and the gastrointestinal lumen[60]. 
Transpapillary/transductal endoscopic drainage is 
recommended for PPCs that communicate with the 
main PD or one of its side branches located in the head 
or the body of the pancreas. A limited number of PPCs 
may be drained via a transpapillary insertion of a stent 
that bridges the main pancreatic duct or a disrupted 
side branch. A favourable predictor of successful 
therapy is a dilated Wirsung duct above a stenotic area 
underneath the stent[4,7,61,62]. 
This technique involves pancreatic endoscopic 
sphincterotomy, balloon dilatation of the commonly 
detected PD strictures, and insertion of a guidewire 
through the duct directly into the pseudocyst cavity. 
Thereafter, a plastic stent of 5 F to 7 F (up to 10 F) 
in diameter is inserted over the wire[4,23,63­65]. The 
duration of stenting depends on the clinical course of 
PPC regression[23,61]. Stents should be left in place for 
a longer duration because their removal within 2 mo 
is associated with a higher incidence of pseudocyst 
recurrence[66]. Some authors have reported on the 
routine exchange of stents every 6 to 8 wk for as long 
as the PPCs remained unresolved[64].
Transpapillary drainage appears to be a safe and 
effective procedure (the immediate success rate is 
approximately 85%) with low morbidity (6%) and no 
reported mortality. The best results are obtained when 
the pseudocyst is older than 6 mo or smaller than 
60 mm[64,67]. Haemorrhagic complications occurred in 
less than 1% of patients and pancreatitis occurred in 
5%. Stent clogging, which can lead to infection, can 
be treated with stent changes alone. Broad­spectrum 
antibiotics are administered in cases of infected 
PPCs[4,23,61,64,65].
Transmural endoscopic drainage (cystogastrostomy 
or cystoduodenostomy) is indicated for pseudocysts 
that do not communicate with the main PD and that 
are compressed against the digestive tract. Drainage 
of the cyst fluid by the trans­mural approach is 
achieved via the insertion of a stent between the 
pseudocyst and the gastric lumen (cystogastrostomy) 
or between the pseudocyst and the duodenal lumen 
(cystoduodenostomy). The drainage procedure 
may be performed either by direct endoscopy as a 
“semi­blind” procedure if an impression caused by 
the cyst is present, or by EUS guidance. Technically, 
cystoduodenostomy should be given preference over 
cystogastrostomy if both routes are deemed equally 
feasible. Direct endoscopic drainage can be performed 
only if the PPC is located next to the gastric or the 
duodenal lumen. The site of transmural puncture for a 
direct endoscopic intervention should be determined 
visually and fluoroscopically by an observed bulge that 
represents the extrinsic compression of the collection 
into the gut lumen[2,68­71]. Once the bulge is located, its 
apex can be identified as the optimal needle insertion 
site. After needle puncture and aspiration of the 
pseudocyst content (for biochemical and cytological 
analyses), a guidewire should be inserted along which 
an incision can be made with either a diathermic 
coagulation probe or a needle­knife papillotome. Once 
access has been achieved, a double pigtail catheter 
can be introduced into the cyst over the wire. The 
European Society of Gastrointestinal Endoscopy (ESGE) 
recommends the insertion of at least two double­
pigtail plastic stents. Transmural stents should not be 
retrieved before complete resolution of the PPC as 
determined by cross­sectional imaging, and not before 
2 mo of stenting[23,65­67,72­74]. 
However, a bulge is often absent with smaller 
collections, collections with low serum albumin, and 
collections in or near the pancreatic tail. Therefore, to 
minimize the risk of complications such as the puncture 
of adjacent structures, bleeding, and perforation, EUS 
is increasingly used to perform ED[2,75]. Randomized 
clinical trials of endoscopic transmural drainage 
with and without EUS guidance showed that EUS­
visualization had an advantage over conventional 
ED[68,69]. Even in large bulging pseudocysts, the EUS­
guided drainage is superior to the purely endoscopic 
approach because the puncture of vascular structures 
and bleeding into the collection can be avoided during 
and immediately after the procedure by Doppler 
sonographic visualization[2,20,76]. The use of EUS­guided 
drainage has been reported, especially for PPCs that 
do not bulge onto the gut wall or PPCs with parietal 
vessels due to portal hypertension[4,32,64,77]. The stent 
type used for endoscopic drainage is currently a major 
area of interest. Conventional drainage with plastic 
stents has its limitations. A covered self­expandable 
metallic stent is an alternative to conventional drainage 
with plastic stents because it offers the option of access 
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to the fistula via a larger diameter for drainage, which 
may increase the final success rate. One problem with 
covered self expandable metallic stent is dislodgement, 
so a metallic stent with flared or looped ends at both 
extremities may be the best option[78­80]. 
The advantages of the endoscopic approach 
compared with PCD include internal drainage and 
avoidance of external fistulae, but limitations include 
the need for multiple repeated procedures under 
sedation or anaesthesia; it is also necessary that 
the location of the PPC be further than 1­1.5 cm 
from the gut wall[20,65,67,81]. Moreover, in the case of 
superinfection or drainage problems, the monitoring, 
catheter manipulation and the analysis of cystic 
content are very difficult by ED[8,11,21,82]. A combination 
of a percutaneous approach with endoscopic tran­
smural drainage can prevent external fistulae and 
avoid repetitive endoscopic interventions[83]. 
Some authors advocate the use of a combination 
of transmural and transpapillary techniques to drain 
pseudocysts. They have used ERCP in the same endo­
scopic session to assess and treat any PD leakage; 
when PD leaks are evident, ERCP is also used for 
the placement of PD stents to bridge the leak site 
or stricture. Thus, when the treatment of the cause 
of the pseudocyst (i.e., the duct leak) is possible by 
placement of concomitant PD stents, this has been 
shown to yield better outcomes[13,61,81,84]. Additionally, 
in patients with disconnected duct syndrome, 
transgastric stent removal results in a lack of a conduit 
for drainage of pancreatic secretions, which leads to 
pseudocyst recurrence[13,85]. 
Laparoscopic surgery
The classic open surgical approach for the treatment 
of PPC requires a laparotomy with attendant risks of 
morbidity and mortality. The development of advanced 
laparoscopic techniques and technologies offer new 
modalities for the treatment of PPCs. Laparoscopic 
surgery is a method in which the lumen of the PPC 
is anastomosed either to the posterior stomach wall 
or to the jejunum with a linear endoscopic stapler or 
with laparoscopic suturing techniques; this provides 
ongoing internal drainage and decompression of the 
PPC[4,7,23,86,87].
Laparoscopic drainage of mature PPCs is usually 
the definitive treatment because it is associated with 
a low complication rate and a good outcome in the 
postoperative follow­up period. Currently, most PPCs 
can be approached and managed by a laparoscopic 
approach, which is due to the availability of advanced 
imaging systems and cameras, better haemostatic 
equipment and excellent suturing skills[23,88]. Laparo­
scopic procedures for PPC include pancreatic pseudocy­
stogastrostomy, pseudocystoduodenostomy, and 
pseudocystojejunostomy.
Cystogastrostomy is the most commonly used 
laparoscopic procedure, and it can be performed via 
the endogastric, transgastric, or exogastric routes. In 
cases where pseudocysts contain significant debris 
because of the larger size of the stoma that is created, 
laparoscopy seems to have a distinct advantage over 
endoscopic drainage[4,7,23]. 
Several authors reported that laparoscopic 
drainage was associated with low morbidity (early 
postprocedure bleeding and infection), rapid recovery, 
and recurrence rates comparable to those reported 
for open surgery. The disadvantage of laparoscopic 
surgery is that it may not be suitable for patients who 
are unfit to undergo general anaesthesia or for patients 
who had undergone extensive previous abdominal 
surgery. Although laparoscopic management has been 
reported with encouraging results, long­term follow­up 
results have yet to show equivalence to those of open 
surgery. Additionally, randomized controlled trials that 
compare PCD, laparoscopic and ED techniques for the 
management of PPCs are required[7,8,23,89]. 
CONCLUSION
PPC usually runs asymptomatically and its clinical 
presentation mainly occurs in case of complications 
during its clinical course. Once a PPC is diagnosed, it 
must be determined whether it can be treated conser­
vatively with the hope of spontaneous resolution, or if 
an intervention is necessary to prevent complications. 
The setting of conservative management of PPCs is 
still poorly evaluated. Several studies have reported 
that some patients with PPCs can be managed 
conservatively with supportive medical care if the 
presenting symptoms can be controlled. 
If intervention is necessary, it must be determined 
whether surgical treatment, PCD, or ED is the best 
approach. Much overlap exists in the various treatment 
options offered by interventional radiologists, gastro­
enterologists, and surgeons, and often a combined 
approach is needed. Several conditions must be met 
to achieve the complete obliteration of the cyst cavity. 
PD anatomy is an important factor in the results of the 
treatment. When PPC-PD communication is identified, 
the mean duration of drainage increases to weeks or 
months, depending on the condition of the PD. The 
recovery of disrupted PD is the main prognostic factor 
for successful treatment of PPC regardless of the 
treatment method used. 
Traditionally, symptomatic PPC has been treated 
by surgical internal drainage. However, this treatment 
involves considerable surgical trauma and general 
anaesthesia. 
The recent trend in the management of sympto­
matic PPC has moved toward less invasive approaches 
such as ED, image­guided PCD and minimal invasive 
surgery.
ED of PPCs may be performed by a trans­papillary 
or a trans­mural approach and is suitable because 
most PPCs lie adjacent to the stomach. The major 
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advantage of the endoscopic approach is that it creates 
a permanent pseudocysto­gastric track with no spillage 
of pancreatic enzymes, which reduces the risks of 
formation of pancreatico-cutaneous fistulas; this is in 
contrast to PCD. Moreover, PCD that persists too long 
is not practical, especially for young and professionally 
active patients. Therefore, some authors suggest that 
ED should be the preferred modality for PPCs that 
are located immediately adjacent to the gastric or 
duodenal wall. 
However, with these potential drainage problems 
(which could appear with both techniques), the 
monitoring, manipulation or change of stent, and 
the analysis of cystic content are very difficult or 
impossible to perform endoscopically, unlike the PCD 
approach. Moreover, PCD is less aggressive compared 
with surgical and endoscopic (especially with ERCP) 
methods, is suitable for the treatment of all PPCs 
regardless of their location and can be performed 
without general anaesthesia. Therefore, this treatment 
option is especially recommended for patients who are 
unsuitable for more aggressive methods and for those 
at a high risk for complications of general anaesthesia.
Some authors advocate the use of a combination 
of transmural and transpapillary techniques to drain 
pseudocysts. Some have used ERCP in the same 
endoscopic session to assess and treat any PD leakage, 
and when PD leaks were evident, ERCP was used for 
the placement of PD stents to bridge the leak site or 
stricture. However, because it has not been clearly 
confirmed that the introduction of stents leads to 
permanent recovery of PD and permanent cessation of 
the leakage of pancreatic juice after the stent removal, 
the use of this intervention is questionable. The reason 
for this is that it may represent overtreatment in 
these patients, given the mechanical trauma of the 
placement and the removal of the PD stent, that the 
two demanding interventions (ERCP) are performed 
under conscious sedation, and the cost-benefit effect.
Laparoscopic management has been reported with 
encouraging results, but long­term follow­up results 
have yet to show equivalence to open surgery and 
other minimally invasive methods. The disadvantage of 
laparoscopic surgery is that it may not be suitable for 
patients who are unfit to undergo general anaesthesia 
or for patients with a history of extensive previous 
abdominal surgery. 
Currently, few randomized controlled studies 
have been performed that compare the various 
minimally invasive approaches in the management 
of PPCs. Several groups worldwide have developed 
new minimally invasive approaches for the treatment 
of PPC. Applicability of these techniques is highly 
dependent on the availability of specialized expertise 
and multidisciplinary teams that are dedicated to the 
management of pancreatic diseases. This review article 
is intended to help physicians base their therapeutic 
decisions about minimally invasive management of 
PPCs on the current state of therapeutic technology 
and published data.
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